Perry, George

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.

Abeta42 Altering Compounds: Mechanisms of Action

Golde, Todd E

1 August 2008 - 31 May 2013
NATIONAL INSTITUTE ON AGING
Total Funding: $ 532,692

A great deal of evidence supports the hypothesis that selective targeting of Abeta42 may be an ideal therapeutic strategy to prevent and possibly treat Alzheimer's disease (AD), the major cause of dementia among the elderly. We have previously reported that select NSAIDS were capable of selectively modulating Abeta42. More recently, we have found that numerous compounds increase Abeta42. Abeta42 modulating agents (generically referred to as gamma-secretase modulators or GSMs) minimally alter total Abeta production but shift the gamma-secretase cleavage site. Abeta42 lowering GSMs increase the production of shorter Abeta peptides and raising agents decrease the levels of shorter Abeta peptides. Current data using novel photoaffinity ligands that modulate Abeta42 cleavage indicate that Abeta42 modulating agents alter production and aggregation of Abeta by binding to a site within the Abeta region of APP carboxyl terminal fragments (CTFs). We hypothesize that binding of the Abeta region of APP CTFs alters the conformation of the APP CTF or its position in the membrane resulting in altered gamma-secretase cleavage, and following cleavage compound binding alters Abeta aggregation. We outline a number of studies to extend our current data that support this hypothesis. We will also evaluate the linked hypotheses regarding the in vivo mechanism of action of Abeta42 lowering NSAIDs and other Abeta42 altering agents. We will perform chronic dosing studies with drug-like Abeta42 lowering and raising agents in APP and BRI-Abeta42 mouse models to evaluate the relative contribution of altering Abeta42 production vs. altering aggregation with respect to effect on Abeta loads and other AD-like pathologies. We will also determine if elevations in shorter Abeta peptides are protective. For these later studies we will use recombinant adenoassociated virus (rAAV) to deliver BRI-Abeta fusion constructs encoding Abeta 1-34, 1-37, and 1-38 to the brain of neonatal APP mice. This methodology creates "somatic brain transgenics" and will allow us to rapidly evaluate the effects of shorter Abeta peptides on Abeta deposition. Effects on Abeta deposition and synaptic transmission will be evaluated. The influence of shorter Abeta peptides on Abeta42 aggregation in vitro will also be evaluated in vitro. These studies should provide additional insight into the mechanisms whereby Abeta42 modulating agents shift Abeta cleavage and how they exert their protective effects in vivo. PUBLIC HEALTH RELEVANCE: A great deal of evidence supports the hypothesis that selective targeting of Abeta42 may be an ideal therapeutic strategy to prevent and possibly treat Alzheimer's disease (AD), the major cause of dementia among the elderly. The proposed studies should provide additional insight into the mechanisms whereby Abeta42 modulating agents shift Abeta cleavage and how they exert their protective effects in vivo. These studies will thereby inform future therapeutic development of this class of potential AD therapeutics.

5 Resulting Publications

• 1.

  2011

  Thomas L Kukar; Thomas B Ladd; Paul Robertson; Sean A Pintchovski; Brenda Moore; Maralyssa A Bann; Zhao Ren; Karen Jansen-West; Kim Malphrus; Simone Eggert; et al.

  Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane region.

  The Journal of biological chemistry 2011;286(46):39804-12.

• 2.

  2010

  Todd E Golde; Leonard Petrucelli; Jada Lewis

  Targeting Abeta and tau in Alzheimer's disease, an early interim report.

  Experimental neurology 2010;223(2):252-66.

• 3.

  2010

  Paramita Chakrabarty; Carolina Ceballos-Diaz; Amanda Beccard; Christopher Janus; Dennis Dickson; Todd E Golde; Pritam Das

  IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice.

  Journal of immunology (Baltimore, Md. : 1950) 2010;184(9):5333-43.

• 4.

  2010

  Paramita Chakrabarty; Karen Jansen-West; Amanda Beccard; Carolina Ceballos-Diaz; Yona Levites; Christophe Verbeeck; Abba C Zubair; Dennis Dickson; Todd E Golde; Pritam Das

  Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010;24(2):548-59.

• 5.

  2009

  Carlo Sala Frigerio; Thomas L Kukar; Abdul Fauq; Paul C Engel; Todd E Golde; Dominic M Walsh

  An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.

  Biochemistry 2009;48(46):10894-904.

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.